Literature DB >> 3060211

Stimulant treatment for the neurobehavioural sequelae of traumatic brain injury.

C T Gualtieri1, R W Evans.   

Abstract

The subject of stimulant treatment for patients with neurobehavioural sequelae of traumatic brain injury (TBI) has received a good deal of recent attention, although there have to date been no controlled studies published. This is a description of 15 TBI patients who received treatment with the psychostimulant methylphenidate, in a double-blind, placebo-controlled cross-over study, with behavioural and neuropsychological ratings. Three subjects remained on the drug for a year after the acute study, and were subsequently studied in a double-blind, placebo-controlled reversal. The results support the idea that at least some symptomatic improvement may be gained from low-dose stimulant treatment, although the statistical analysis of the data was compromised by the occurrence of carryover effects from one drug condition to another. This, in itself, is an interesting discovery, because such effects have never been observed in stimulant studies of other patient groups. There are clear implications for the design of further studies in this area. The long-term effects of methylphenidate treatment were not at all impressive, however. Although the findings presented below may be subject to differing interpretation, it is conceivable that stimulants act to advance the course of cortical recovery following TBI.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3060211     DOI: 10.3109/02699058809150898

Source DB:  PubMed          Journal:  Brain Inj        ISSN: 0269-9052            Impact factor:   2.311


  21 in total

1.  Targeting Dopamine in Acute Traumatic Brain Injury.

Authors:  James W Bales; Anthony E Kline; Amy K Wagner; C Edward Dixon
Journal:  Open Drug Discov J       Date:  2010

Review 2.  Catecholaminergic based therapies for functional recovery after TBI.

Authors:  Nicole D Osier; C Edward Dixon
Journal:  Brain Res       Date:  2015-12-19       Impact factor: 3.252

Review 3.  Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults.

Authors:  Susan E Hardy
Journal:  Am J Geriatr Pharmacother       Date:  2009-02

4.  The effect of environmental enrichment on substantia nigra gene expression after traumatic brain injury in rats.

Authors:  Samuel S Shin; James W Bales; Hong Q Yan; Anthony E Kline; Amy K Wagner; James Lyons-Weiler; C Edward Dixon
Journal:  J Neurotrauma       Date:  2013-02-05       Impact factor: 5.269

5.  Methylphenidate modulates sustained attention and cortical activation in survivors of traumatic brain injury: a perfusion fMRI study.

Authors:  Junghoon Kim; John Whyte; Sunil Patel; Eduardo Europa; Jiongjiong Wang; H Branch Coslett; John A Detre
Journal:  Psychopharmacology (Berl)       Date:  2011-12-28       Impact factor: 4.530

6.  Methylphenidate and Memory and Attention Adaptation Training for Persistent Cognitive Symptoms after Traumatic Brain Injury: A Randomized, Placebo-Controlled Trial.

Authors:  Brenna C McDonald; Laura A Flashman; David B Arciniegas; Robert J Ferguson; Li Xing; Jaroslaw Harezlak; Gwen C Sprehn; Flora M Hammond; Arthur C Maerlender; Carrie L Kruck; Karen L Gillock; Kim Frey; Rachel N Wall; Andrew J Saykin; Thomas W McAllister
Journal:  Neuropsychopharmacology       Date:  2016-11-22       Impact factor: 7.853

7.  Cognitive Impairment Following Traumatic Brain Injury.

Authors:  David B. Arciniegas; Kerri Held; Peter Wagner
Journal:  Curr Treat Options Neurol       Date:  2002-01       Impact factor: 3.598

Review 8.  Stimulant drugs.

Authors:  P J Santosh; E Taylor
Journal:  Eur Child Adolesc Psychiatry       Date:  2000       Impact factor: 4.785

Review 9.  Mood disorders after TBI.

Authors:  Ricardo E Jorge; David B Arciniegas
Journal:  Psychiatr Clin North Am       Date:  2014-01-14

Review 10.  Pharmacotherapy of traumatic brain injury: state of the science and the road forward: report of the Department of Defense Neurotrauma Pharmacology Workgroup.

Authors:  Ramon Diaz-Arrastia; Patrick M Kochanek; Peter Bergold; Kimbra Kenney; Christine E Marx; Col Jamie B Grimes; L T C Yince Loh; L T C Gina E Adam; Devon Oskvig; Kenneth C Curley; Wanda Salzer
Journal:  J Neurotrauma       Date:  2014-01-15       Impact factor: 5.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.